- Pear Therapeutics ( NASDAQ: PEAR ) and Spero Health have extended a partnership for the former to provide the latter prescription digital therapeutics for the treatment of substance use and opioid use disorders.
- Shares are up 4% in premarket trading.
- The extended arrangement will allow eligible Spero patients in 99 locations to the reSET and reSET-O programs for each condition.
- Both programs utilize cognitive behavioral therapy as a adjunct to outpatient treatment.
- Spero has already implemented the programs at 14 locations in Kentucky.
- Ready why Seeking Alpha contributor Valkyrie Trading Society rates Pear ( PEAR ) a buy.
For further details see:
Pear Therapeutics, Spero expand partnership for digital therapeutics for substance use